Section Arrow
CCCC.NASDAQ
- C4 Therapeutics
Quotes are at least 15-min delayed:2026/05/18 11:27 EDT
Regular Hours
Last
 3.29
-0.27 (-7.58%)
Day High 
3.58 
Prev. Close
3.56 
1-M High
3.95 
Volume 
890.92K 
Bid
3.28
Ask
3.29
Day Low
3.22 
Open
3.53 
1-M Low
2.52 
Market Cap 
393.62M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.21 
20-SMA 3.05 
50-SMA 2.88 
52-W High 3.95 
52-W Low 1.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.10/-0.98
Enterprise Value
447.23M
Balance Sheet
Book Value Per Share
2.12
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
35.95M
Operating Revenue Per Share
0.18
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VRAXVirax Biolabs Group Limited0.4265+0.273+177.85%-- 
AIMAIM ImmunoTech Inc.0.6247+0.3717+146.92%-- 
GOVXGeoVax Labs Inc.3+1.77+143.90%-- 
CMNDClearmind Medicine Inc.0.4055-0.1145-22.02%-- 
LABTLakewood-Amedex Biotherapeutics Inc1.155-0.345-23.00%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.